|
| 双环醇序贯治疗拉米夫定停药患者的临床试验 |
| Clinical Study of Sequential Treatment of Bicyclo-ethanol in Patients after Treatment of Lamivudine |
| 投稿时间：2005-03-31 |
| DOI： |
| 中文关键词: 慢性乙型肝炎 双环醇 拉米夫定 临床试验 |
| 英文关键词:Chronic hepatitis B Bicyclo-ethanol Lamivudine Clinical trial |
| 基金项目: |
| 黄元成 喻国萍 许东 张振纲 田德英 齐俊英 |
| [1]华中科技大学同济医学院附属同济医院感染科,武汉430030 [2]湖南省华容县人民医院内一科,武汉430030 |
| 摘要点击次数: 1097 |
| 全文下载次数: 105 |
| 中文摘要: |
| 目的：观察双环醇序贯治疗拉米夫定停药患者肝功能及HBV-DNA变化情况，评价其序贯治疗拉米夫定停药患者的临床应用价值。方法：将60例服用拉米夫定〉6个月的慢性乙型肝炎轻型患者分为治疗组（A组）：停用拉米夫定的同时开始服用双环醇（50mg，tid），疗程6个月；对照组（B组）：停药观察6个月。两组患者每月检测肝功能，每3个月观察HBV-DNA的变化情况。结果：患者肝功能异常多发生在拉米夫定停药2～5个月，其中对照组患者ALT异常率分别为46．7％，83．3％，76．6％，34．5％，显著高于双环醇治疗组的10．0％，30．0％，20．0％，6．67％（P〈0．05），停药3，4个月时，两组差异显著（P〈0．001）；而SB异常率停药4个月时为27．6％，显著高于治疗组的3．4％；ALB异常率停药4～6个月分别为34．5％，24．1％和20．7％，显著高于治疗组（P〈0．05）；治疗组HBV-DNA停药3个月、6个月时，略低于对照组，但差异无统计学意义。结论：双环醇能够明显改善拉米夫定停药患者的临床症状，显著降低肝功能异常率，而对HBV-DNA的转阳率没有明显影响，可作为拉米夫定停药患者序贯治疗的有效药物之一。 |
| 英文摘要: |
| Objective:To evaluate its effects on HBV replication, we conducted a sequential administration of lamivudine and to observe the change of liver function and HBV-DNA. Method:60 HBV patients with at least six months history of lamivudine administration were randomly assigned into 2 groups. Group A (treatment group) was treated with a sequential administration of lamivudine and bicyclo-ethanol, group B ( control group) was treated only with lamivudine for six months and the groups were observed for another 6 months. The serum samples were assayed for Alamine aminotrans-ferase(ALT) monthly and the quantity of HBV-DNA (quantitative PCR) every three months. Result:Increased ALT levels were observed from the second to the fifth month after the drug was withdrawn. The activity indexes of the liver function were 46. 7% , 83. 3% , 76. 6% and 34.5% in group B and 10.0% , 30.0% , 20.0% and 6.67% in group A. The change rate of ALT in group B increased significantly ( P <0. 05) , especially in the 3rd and 4th month ( P <0. 001) . In the forth month, SB was 27. 6% and 3.4% in group A and group B respectively:ALB was 34. 5% , 24. 1 % and 24. 7% in 4th, 5th and 6th respectively after the treatment. There was some significant difference between the two groups (P < 0. 05 ) . Conclusion:This sequential administration of lamivudine and bicyclo-ethanol can improve the clinical symptom and decrease the change rate of ALT, but there is no significant effect on the quantity of HBV-DNA. Bicyclo-ethanol may be used as one of the effective drugs after the stoppage of the administration of the Lamivudine. |
| 查看全文 查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
